Patent Assignment
Reel/Frame 026561/0978
SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS
Recorded: 2011-07-08
Received: 2011-07-08
Pages: 12
Assignor
ENDO PHARMACEUTICALS INC.
Executed: 2011-06-17
Assignee
MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
1 PIERREPONT PLAZA, BROOKLYN, NY, 11201, UNITED STATES
Covered Applications
(45)
METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITUS
App. No. 12/922,038
→
METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS
App. No. 12/515,429
→
AN ANTI-MISUSE MICROPARTICULATE ORAL PHARMACEUTICAL FORM
App. No. 12/638,739
→
ABUSE-PROOFED ORAL DOSAGE FORM
App. No. 12/140,470
→
ABUSE-PROOFED DOSAGE FORM
App. No. 12/140,444
→
PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED DOSAGE FORM
App. No. 12/140,609
→
ABUSE-PROOF DOSAGE FORM
App. No. 12/140,665
→
PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED SOLID DOSAGE FORM
App. No. 12/140,496
→
PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED DOSAGE FORM
App. No. 12/140,718
→
SUSTAINED RELEASE FORMULATIONS OF NALBUPHINE
App. No. 12/154,496
→
METHOD OF INHIBITING INFLAMMATORY PAIN
App. No. 11/774,816
→
SUSTAINED RELEASE MATRIX SYSTEMS FOR HIGHLY SOLUBLE DRUGS
App. No. 11/729,024
→
Oral dosage form comprising an antimisuse system
App. No. 11/651,577
→
DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE
App. No. 10/567,594
→
Sustained release formulations of nalbuphine
App. No. 11/509,347
→
ABUSE-PROOFED DOSAGE FORM
App. No. 11/462,216
→
Process for the production of an abuse-proofed dosage form
App. No. 11/471,438
→
Anti-misuse microparticulate oral pharmaceutical form
App. No. 11/439,432
→
Phosphate salts of 6-dimethylaminomethyl-1-(3-methoxyphenyl)-1,3-dihydroxy-cyclohexane compounds
App. No. 11/361,954
→
Process for the production of an abuse-proofed dosage form
App. No. 11/348,276
→
Abuse-proofed dosage form
App. No. 11/349,537
→
ABUSE-PROOFED DOSAGE FORM
App. No. 11/349,544
→
Crush resistant delayed-release dosage forms
App. No. 11/348,295
→
Pharmaceutical composition containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with delayed active ingredient release
App. No. 11/334,344
→
COMBINATION OF SELECTED ANALGESICS AND COX-II INHIBITORS
App. No. 11/133,190
→
COMPOSITIONS AND METHODS FOR THE TREATMENT OF URINARY INCONTINENCE
App. No. 10/978,565
→
DELAYED RELEASE DOSAGE FORMS
App. No. 10/943,356
→
Process for the production of an abuse-proofed solid dosage form
App. No. 10/890,703
→
PROCESS FOR PRODUCTION OF AN ABUSE-PROOFED SOLID DOSAGE FORM
App. No. 10/890,704
→
Abuse-proofed oral dosage form
App. No. 10/890,763
→
Combination of selected opioids with muscarine antagonists for treating urinary incontinence
App. No. 10/803,187
→
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR RELIABLE ACHIEVEMENT OF ACCEPTABLE SERUM TESTOSTERONE LEVELS
App. No. 10/798,780
→
Abuse-proofed dosage form
App. No. 10/718,112
→
SUSTAINED RELEASE FORMULATIONS OF METFORMIN
App. No. 10/630,239
→
PENETRATION ENHANCING AND IRRITATION REDUCING SYSTEMS
App. No. 10/389,715
→
METHOD FOR THE ENZYMATIC RESOLUTION OF THE RACEMATES OF AMINOMETHYL-ARYL-CYCLOHEXANOL DERIVATIVES
App. No. 10/203,031
→
HYALURONIC ACID IN THE TREATMENT OF CANCER
App. No. 10/168,327
→
INTRADERMAL-PENETRATION AGENTS FOR TOPICAL LOCAL ANESTHETIC ADMINISTRATION
App. No. 10/201,901
→
SUSTAINED RELEASE FORMULATIONS OF OXYMORPHONE
App. No. 10/189,932
→
COMPOSITION AND METHOD FOR INDUCING APOPTOSIS IN PROSTATE CANCER CELLS
App. No. 09/937,643
→
PENETRATION ENHANCING AND IRRITATION REDUCING SYSTEMS
App. No. 09/963,287
→
METHOD FOR THE TREATMENT OF INFLAMMATION
App. No. 09/857,333
→
CHEMOTHERAPEUTIC COMPOSITION AND METHOD
App. No. 09/857,332
→
SUSTAINED-RELEASE COMPOSITION INCLUDING AMORPHOUS POLYMER
App. No. 09/877,330
→
SYSTEM FOR OSMOTIC DELIVERY OF PHARMACEUTICALLY ACTIVE AGENTS
App. No. 09/872,173
→